Welcome to CREANT!

CREANT is the acronym of the Center for Radiopharmaceuticals Antwerp.

What we do

We create innovative radiopharmaceutical solutions that will improve the lives of cancer patients around the globe.

Discover our research

Our mission

CREANT’s mission is to ensure that the right cancer treatment is given to the right patient at the right time. By developing radiopharmaceuticals that target specific cancer markers we aim to provide an individually tailored therapeutic intervention.

Meet the team

CREANT is driven by the enthousiasm of a large number of people.

Meet the team 

Creating innovative radiopharmaceuticals for tomorrow’s theranostics.


Impressions of our mini-symposium on Cancer Radiotheranostics

Take a look at some impressions of our recent mini-symposium on radiotheranostics! A big thank you to all the incredible speakers who shared their expertise and insights on this transformative field. During this symposium Karuna Adhikari successfully defended her PhD dissertation!


Improved FAP-radiotheranostics for personalized cancer treatment

Improved FAP-radiotheranostics for personalized cancer treatment Cancer-associated fibroblasts (CAFs) are a group of tumor stromal cells typically associated with cancer growth and metastasis. These CAFs show high expression of the fibroblast activation protein (FAP) on the cell membrane. Due to the selective FAP expression and cancer-specific distribution, CAFs have emerged as a promising cancer diagnostic marker and an attractive therapeutic target.


European Molecular Imaging Meeting (EMIM) 2023 Award

Louis Lauwerys a PhD student from CREANT has won a poster award at the European Molecular Imaging Meeting (EMIM) in Salzburg (Austria) for his work on the design and evaluation of a novel caspase-3 radiotracer for monitoring apoptosis in response to cancer therapy. Congratulations Louis!


Our partners

University of Antwerp
Molecular Imaging Center Antwerp (MICA)
Antwerp University Hospital (UZA)